Nucleus Network expands early phase trial capacity in Australia with acquisition of Q-Pharm
11 February 2019 Nucleus Network recently announced its acquisition of Q-Pharm, a 62-bed dedicated early-phase clinical trial facility based in the Herston health precinct in Brisbane. Q-Pharm was previously wholly owned by the QIMR Berghofer Medical Research Institute.…
4th Annual CEO Remuneration Report – Wexford Hayes
31 January 2019 This 4th annual CEO Remuneration report reviews the remuneration of the top 100 public companies listed on the Australian Securities Exchange for the Health Care & Biotechnology Sector. The report provides insight into remuneration in…
Sienna furthers its Global Expansion with Distributor for the Republic of Korea
22 January 2019 Highlights: Mirax Corporation appointed as exclusive distributor for Korea Important expansion of commercial opportunity in high-growth Asian IVD market Sienna Cancer Diagnostics Ltd a medical technology company developing and commercialising innovative cancer related tests, continues…
Super Charging The Immune System to Fight Cancer
22 January 2019 Innovative immunotherapies for cancer are a step closer to reality thanks to an agreement between Australia’s Cartherics Pty Ltd and Seoul-based ToolGen Inc. The agreement, signed in Melbourne on 21 January 2019, enables the companies…
Imagion Biosystems teams with Planet Innovation for MagSense™ instrument development
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet Innovation, a healthtech innovation and commercialization company, are pleased to announce that they have entered into a…
Design + Industry is now ISO 13485:2016 certified
BioMelbourne Network member Design + Industry (D+I) is proud to announce that they have achieved ISO 13485:2016 certification — the culmination of a four-year effort and recognition of their commitment to design and engineering excellence in the development…
2019 ARCS Annual Conference: call for session and program proposals extended
Interested parties from industry, research institutions, government and academia involved in development through to commercialisation of therapeutics (from bench to bedside) are invited to submit session proposals and program suggestions for the 2019 ARCS Annual Conference to be…
BioEYES looking for industry partners
3 December 2018 BioEYES Australia is a science outreach program that covers curricula in genetics, cell biology and developmental biology, but more importantly excites students about the thrill of scientific discovery. Over a 1 week incursion, students set…
ARC Centre for Personalised Therapeutics Technologies launches in Melbourne
22 November 2018 The ARC Centre for Personalised Therapeutics Technologies launched in Melbourne this week. The centre, headquartered at the Department of Pharmacology and Therapeutics at the University of Melbourne, aims to advance and deploy new technologies that will remove…
Novartis and BioCurate announce first collaboration to accelerate early stage drug discovery
31 October 2018 Biomedical research company BioCurate Pty Ltd and Novartis today announced that they will collaborate on early stage drug discovery projects that have potential to address an unmet need. This collaboration marks BioCurate’s first with the…
Watermark a first-mover with customised website live chat platform
Being on the leading edge of innovation and intellectual property, Watermark is paving the digital path for IP attorney and legal services firms with the unveiling of a website chat bot. Executive General Manager Mark Bisset says the…
Immutep enters into clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer
Immutep Limited is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha…
